{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:40:34Z","timestamp":1792518034682,"version":"4.5.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"Importance<\/jats:title>Personalized surveillance, prophylaxis, and cancer treatment options for individuals with hereditary cancer predisposition are informed by results of germline genetic testing. Improvements to genomic technology, such as the availability of RNA sequencing, may increase identification of individuals eligible for personalized interventions by improving the accuracy and yield of germline testing.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the cumulative association of paired DNA and RNA testing with detection of disease-causing germline genetic variants and resolution of variants of uncertain significance (VUS).<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Paired DNA and RNA sequencing was performed on individuals undergoing germline testing for hereditary cancer indication at a single diagnostic laboratory from March 2019 through April 2020. Demographic characteristics, clinical data, and test results were curated as samples were received, and changes to variant classification were assessed over time. Data analysis was performed from May 2020 to June 2023.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Main outcomes were increase in diagnostic yield, decrease in VUS rate, the overall results by variant type, the association of RNA evidence with variant classification, and the corresponding predicted effect on cancer risk management.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 43\u202f524 individuals were included (median [range] age at testing, 54 [2-101] years; 37\u202f373 female individuals [85.7%], 6224 male individuals [14.3%], and 2 individuals of unknown sex [&amp;lt;0.1%]), with 43\u202f599 tests. A total of 2197 (5.0%) were Ashkenazi Jewish, 1539 (3.5%) were Asian, 3077 (7.1%) were Black, 2437 (5.6%) were Hispanic, 27\u202f793 (63.7%) were White, and 2049 (4.7%) were other race, and for 4507 individuals (10.3%), race and ethnicity were unknown. Variant classification was impacted in 549 individuals (1.3%). Medically significant upgrades were made in 97 individuals, including 70 individuals who had a variant reclassified from VUS to pathogenic\/likely pathogenic (P\/LP) and 27 individuals who had a novel deep intronic P\/LP variant that would not have been detected using DNA sequencing alone. A total of 93 of 545 P\/LP splicing variants (17.1%) were dependent on RNA evidence for classification, and 312 of 439 existing splicing VUS (71.1%) were resolved by RNA evidence. Notably, the increase in positive rate (3.1%) and decrease in VUS rate (\u22123.9%) was higher in Asian, Black, and Hispanic individuals combined compared to White individuals (1.6%; P<\/jats:italic>\u2009=\u2009.02; and \u22122.5%; P<\/jats:italic>\u2009&amp;lt;\u2009.001).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Findings of this diagnostic study demonstrate that the ability to perform RNA sequencing concurrently with DNA sequencing represents an important advancement in germline genetic testing by improving detection of novel variants and classification of existing variants. This expands the identification of individuals with hereditary cancer predisposition and increases opportunities for personalization of therapeutics and surveillance.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2023.5586","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T15:30:31Z","timestamp":1699111831000},"page":"212","source":"Crossref","is-referenced-by-count":45,"title":["Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing"],"prefix":"10.1001","volume":"10","author":[{"given":"Carolyn","family":"Horton","sequence":"first","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Hoang","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Zimmermann","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Young","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Grzybowski","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Durda","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Vuong","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Burks","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Cass","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"LaDuca","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcy E.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Harrison","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Chao","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"},{"name":"University of California, Irvine, School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Karam","sequence":"additional","affiliation":[{"name":"Ambry Genetics, Aliso Viejo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"38","key":"coi230076r1","doi-asserted-by":"publisher","first-page":"6445","DOI":"10.1038\/sj.onc.1207714","article-title":"Highly penetrant hereditary cancer syndromes.","volume":"23","author":"Nagy","year":"2004","journal-title":"Oncogene"},{"issue":"2","key":"coi230076r2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1200\/JCO.2005.10.042","article-title":"Hereditary cancer predisposition syndromes.","volume":"23","author":"Garber","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18","key":"coi230076r3","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline.","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi230076r4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.mayocp.2019.01.042","article-title":"Hereditary cancer syndromes\u2014a primer on diagnosis and management, part 2: gastrointestinal cancer syndromes.","volume":"94","author":"Samadder","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"24","key":"coi230076r5","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.20.03661","article-title":"Therapeutic implications of germline testing in patients with advanced cancers.","volume":"39","author":"Stadler","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi230076r6","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1634\/theoncologist.2020-0697","article-title":"PARP inhibitors and prostate cancer: to infinity and beyond BRCA.","volume":"26","author":"Risdon","year":"2021","journal-title":"Oncologist"},{"issue":"12","key":"coi230076r7","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s11912-022-01340-x","article-title":"Germline genetic testing in breast cancer: systemic therapy implications.","volume":"24","author":"Bhardwaj","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"13","key":"coi230076r8","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1200\/JCO.19.02010","article-title":"Cascading after peridiagnostic cancer genetic testing: an alternative to population-based screening.","volume":"38","author":"Offit","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"coi230076r9","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1002\/ajmg.a.v143a:21","article-title":"Diagnostic utility of array-based comparative genomic hybridization in a clinical setting.","volume":"143A","author":"Baris","year":"2007","journal-title":"Am J Med Genet A"},{"issue":"28","key":"coi230076r10","doi-asserted-by":"publisher","first-page":"12629","DOI":"10.1073\/pnas.1007983107","article-title":"Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.","volume":"107","author":"Walsh","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"coi230076r11","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamaoncol.2018.0644","article-title":"Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer.","volume":"4","author":"Kurian","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"coi230076r12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jmoldx.2019.03.001","article-title":"Multi-gene panel testing of 23,179 individuals for hereditary cancer risk identifies pathogenic variant carriers missed by current genetic testing guidelines.","volume":"21","author":"Neben","year":"2019","journal-title":"J Mol Diagn"},{"issue":"2","key":"coi230076r13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome.","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"coi230076r14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/jama.2022.22843","article-title":"RNA sequencing as a diagnostic tool.","volume":"329","author":"Ketkar","year":"2023","journal-title":"JAMA"},{"key":"coi230076r15","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3389\/fgene.2019.01152","article-title":"RNA-seq perspectives to improve clinical diagnosis.","volume":"10","author":"Marco-Puche","year":"2019","journal-title":"Front Genet"},{"key":"coi230076r16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41698-020-0109-y","article-title":"Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes.","volume":"4","author":"Landrith","year":"2020","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"coi230076r17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.21873\/cgp.20259","article-title":"Clinical utility of functional RNA analysis for the reclassification of splicing gene variants in hereditary cancer.","volume":"18","author":"Agiannitopoulos","year":"2021","journal-title":"Cancer Genomics Proteomics"},{"issue":"10","key":"coi230076r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.13900","article-title":"Assessment of diagnostic outcomes of RNA genetic testing for hereditary cancer.","volume":"2","author":"Karam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"coi230076r19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41525-022-00323-y","article-title":"Mutational and splicing landscape in a cohort of 43,000 patients tested for hereditary cancer.","volume":"7","author":"Horton","year":"2022","journal-title":"NPJ Genom Med"},{"issue":"5","key":"coi230076r20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"coi230076r21","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2469523","article-title":"Beyond DNA: an integrated and functional approach for classifying germline variants in breast cancer genes.","volume":"2016","author":"Pesaran","year":"2016","journal-title":"Int J Breast Cancer"},{"issue":"3","key":"coi230076r23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2018.12.015","article-title":"Predicting splicing from primary sequence with deep learning.","volume":"176","author":"Jaganathan","year":"2019","journal-title":"Cell"},{"issue":"11","key":"coi230076r26","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/humu.v29:11","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.","volume":"29","author":"Plon","year":"2008","journal-title":"Hum Mutat"},{"issue":"9","key":"coi230076r27","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/gim.2017.210","article-title":"Modeling the ACMG\/AMP variant classification guidelines as a Bayesian classification framework.","volume":"20","author":"Tavtigian","year":"2018","journal-title":"Genet Med"},{"issue":"2","key":"coi230076r28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41436-019-0633-8","article-title":"A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients.","volume":"22","author":"LaDuca","year":"2020","journal-title":"Genet Med"},{"issue":"6","key":"coi230076r29","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41436-020-0766-9","article-title":"Blood RNA analysis can increase clinical diagnostic rate and resolve variants of uncertain significance.","volume":"22","author":"Wai","year":"2020","journal-title":"Genet Med"},{"issue":"2","key":"coi230076r30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/gim.2017.96","article-title":"Racial\/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.","volume":"20","author":"Caswell-Jin","year":"2018","journal-title":"Genet Med"},{"issue":"4","key":"coi230076r31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10689-019-00144-6","article-title":"Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European.","volume":"18","author":"Ndugga-Kabuye","year":"2019","journal-title":"Fam Cancer"},{"issue":"10","key":"coi230076r32","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/jnci\/djaa167","article-title":"Racial and ethnic differences in multigene hereditary cancer panel test results for women with breast cancer.","volume":"113","author":"Yadav","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"coi230076r33","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkac002","article-title":"Clinician-reported impact of germline multigene panel testing on cancer risk management recommendations.","volume":"6","author":"Horton","year":"2022","journal-title":"JNCI Cancer Spectr"},{"issue":"11","key":"coi230076r34","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/s41436-020-0876-4","article-title":"Clinical outcomes of a genomic screening program for actionable genetic conditions.","volume":"22","author":"Buchanan","year":"2020","journal-title":"Genet Med"},{"issue":"1","key":"coi230076r35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10897-016-9985-2","article-title":"The clinical utility of next generation sequencing results in a community-based hereditary cancer risk program.","volume":"26","author":"Bunnell","year":"2017","journal-title":"J Genet Couns"},{"issue":"2","key":"coi230076r36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00167","article-title":"Pathogenic variants in less familiar cancer susceptibility genes: what happens after genetic testing?","volume":"2","author":"Hall","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"coi230076r37","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.jmoldx.2020.09.007","article-title":"Improving genetic testing in hereditary cancer by RNA analysis: tools to prioritize splicing studies and challenges in applying American College of Medical Genetics and Genomics guidelines.","volume":"22","author":"Rofes","year":"2020","journal-title":"J Mol Diagn"},{"key":"coi230076r22","doi-asserted-by":"crossref","unstructured":"Walker? LC, de la Hoya? M, Wiggins? GAR, . Application of the ACMG\/AMP framework to capture evidence relevant to predicted and observed impact on splicing: recommendations from the ClinGen SVI Splicing Subgroup.? medRxiv. Preprint posted online February 26, 2023. doi:10.1101\/2023.02.24.23286431?","DOI":"10.1101\/2023.02.24.23286431"},{"key":"coi230076r24","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): genetic\/familial high-risk assessment: breast, ovarian, and pancreatic. Version 1.2021. Accessed October 29, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf"},{"key":"coi230076r25","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): genetic\/familial high-risk assessment: colorectal. Version 1.2021. Accessed October 29, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_colon.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2811619\/jamaoncology_horton_2023_oi_230076_1707941337.85646.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:02:27Z","timestamp":1708012947000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2811619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2023.5586","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}